CareDx, Inc
NASDAQ:CDNAMedical - Diagnostics & Research
+$1.19 today
- Market cap
- $3.91B
- Beta
- 2.48
- P/E (TTM)
- -154.0
- EPS (TTM)
- -$0.16
Volume 0.54M
Average 0.74M
CDNA Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
CareDx, IncNASDAQ: CDNA
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation growth accelerates
Q2 FY2026 stock-based compensation of $10.65M rose 13.1% year over year, ahead of the -28.6% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 8.7% from the prior quarter. Over 3 fiscal years it compounded at -9.2% a year.
Context
- Stock-based compensation amounted to 9.2% of revenue in FY2025, down 10.7 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +13.1% holds above the trailing-twelve-month pace of -28.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 34.86M USD
- Year-over-year change
- -47.5%
- 4-year CAGR
- -0.9%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 34.86M | -47.5% |
| FY2024 | 2024-12-31 | 66.41M | +35.3% |
| FY2023 | 2023-12-31 | 49.09M | +5.4% |
| FY2022 | 2022-12-31 | 46.55M | +29.0% |
| FY2021 | 2021-12-31 | 36.08M | — |
Stock-Based Compensation vs competitors
How CDNA compares with its peers on the latest reported figures
- CDNA's LTM Jun 2026 stock-based compensation of $36.97M is the 3rd largest of the 8 companies compared; the peer median is $35.7M.
- Its year-over-year change of -28.6% is the 5th highest of 7, against a peer median of +3.3%.
- Stock-based compensation amounts to 8.1% of revenue for CDNA, versus a peer median of 7.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $381.42M | +21.6% | +32.5% | 14.1% | |
| LTM Jun 2026 | $48.51M | +20.3% | +17.7% | 8.6% | |
| LTM Jun 2026 | $36.97M | -28.6% | -9.2% | 8.1% | |
| LTM Jun 2026 | $36.96M | -13.6% | +0.6% | 1.8% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | $35.7M | +95.3% | -8.5% | 7.9% |
| LTM Mar 2026 | $32.2M | -31.9% | -2.6% | 3.9% | |
| LTM Mar 2026 | $29.03M | -33.3% | +6.6% | 9.1% | |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $25.54M | — | — | 6.4% |
| Peer median (excluding CDNA) | $35.7M | +3.3% | +3.6% | 7.9% | |
Competitors are the stored peer set for CDNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (30.66M) | (76.61M) | (190.28M) | 52.55M | (21.35M) |
| Depreciation & Amortization | 11.89M | 16.01M | 19.82M | 19.76M | 20.42M |
| Deferred Income Tax | 0 | 0 | 566K | (187K) | 17K |
| Stock-Based Compensation | 36.08M | 46.55M | 49.09M | 66.41M | 34.86M |
| Change in Working Capital | (40.97M) | (14.22M) | 106.03M | (102.31M) | 3.81M |
| Accounts Receivables | (24.42M) | (6.66M) | 16.02M | (13.74M) | 22.52M |
| Inventory | (6.93M) | (2.86M) | 54K | (1.02M) | (4.96M) |
| Accounts Payables | 1.79M | (2.05M) | 2.9M | (5.11M) | 808K |
| Other Working Capital | (11.42M) | (2.64M) | 87.06M | (82.44M) | (14.56M) |
| Other Non-Cash Items | 4.37M | 3.03M | (3.61M) | 1.83M | 4.28M |
| Operating Cash Flow | (19.29M) | (25.24M) | (18.39M) | 38.05M | 42.03M |
| Capital Expenditures | (20.26M) | (24.33M) | (9.24M) | (6.48M) | (5.91M) |
| Acquisitions (Net) | (15.43M) | (610K) | (6.68M) | 0 | 0 |
| Purchases of Investments | (5.5M) | (315.15M) | (201.17M) | (160.29M) | (145.93M) |
| Sales of Investments | 88.91M | 111.59M | 256.04M | 166.92M | 154.67M |
| Other Investing Activities | 0 | 0 | 1.5M | (634K) | 0 |
| Investing Cash Flow | 47.71M | (228.5M) | 40.45M | (483K) | 2.16M |
| Debt Repayment | (66K) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 188.86M | 0 | 0 | 0 | 8M |
| Common Stock Repurchased | 0 | (642K) | (27.54M) | (522K) | (87.77M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (3.15M) | (3.89M) | (2.07M) | (5.08M) | (13.62M) |
| Financing Cash Flow | 185.64M | (4.54M) | (29.61M) | (5.61M) | (93.39M) |
| Effect of Forex Changes | (303K) | 23K | (112K) | 532K | (90K) |
| Net Change in Cash | 213.76M | (258.25M) | (7.66M) | 32.49M | (49.29M) |
| Free Cash Flow | (39.55M) | (49.57M) | (27.63M) | 31.56M | 36.12M |
CareDx, Inc
NASDAQ:CDNA
Intrinsic Alpha fair value
Locked
Current Price
$74.44
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.